Profound Medical Corp. (PRN.TO)
| Previous Close | 10.01 |
| Open | 10.15 |
| Bid | 10.07 x 0 |
| Ask | 10.36 x 0 |
| Day's Range | 10.01 - 10.15 |
| 52 Week Range | 9.55 - 20.44 |
| Volume | |
| Avg. Volume | 4,269 |
| Market Cap | 244.533M |
| Beta (5Y Monthly) | 0.79 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow
TORONTO, April 22, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2024 financial results after market close on Thursday, May 9, 2024. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the
- GlobeNewswire
Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
TORONTO, April 09, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the 2024 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024 at 9:30 a.m. Eastern Time at the Metro Toronto Convention Centre.
- GlobeNewswire
Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results
TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2023. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with Internationa
